SCHEDULE 13G
SCHEDULE 13GSchedule 13G ownership disclosure
Maze Therapeutics Inc
Common Stock, par value $0.001 per share · CUSIP: 578784100
Event date: 2025-02-03
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Frazier Life Sciences Public Fund, L.P.
Shares: 2,376,329.00 · Class: 5.4%
- FHMLSP, L.P.
Shares: 2,376,329.00 · Class: 5.4%
- FHMLSP, L.L.C.
Shares: 2,376,329.00 · Class: 5.4%
- Frazier Life Sciences Public Overage Fund, L.P.
Shares: 701,164.00 · Class: 1.6%
- FHMLSP Overage, L.P.
Shares: 701,164.00 · Class: 1.6%
- FHMLSP Overage, L.L.C.
Shares: 701,164.00 · Class: 1.6%
- Frazier Life Sciences X, L.P.
Shares: 41,719.00 · Class: 0.1%
- FHMLS X, L.P.
Shares: 41,719.00 · Class: 0.1%
- FHMLS X, L.L.C.
Shares: 41,719.00 · Class: 0.1%
- Frazier Life Sciences XI, L.P.
Shares: 74,688.00 · Class: 0.2%
- FHMLS XI, L.P.
Shares: 74,688.00 · Class: 0.2%
- FHMLS XI, L.L.C.
Shares: 74,688.00 · Class: 0.2%
- James N. Topper
Shares: 3,193,900.00 · Class: 7.3%
- Patrick J. Heron
Shares: 3,193,900.00 · Class: 7.3%
- Albert Cha
Shares: 3,077,493.00 · Class: 7.0%
- James Brush
Shares: 3,077,493.00 · Class: 7.0%
- Daniel Estes
Shares: 74,688.00 · Class: 0.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-003423
- Form type
- SCHEDULE 13G
- Filer
- Frazier Life Sciences Public Fund, L.P.
- CIK
- CIK 1863769
- Filed
- Feb 10, 2025
- Reporting period
- Feb 03, 2025
- Description
- Schedule 13G beneficial ownership